Merck & Co., Inc. Stock price

MRK

US58933Y1055

Pharmaceuticals

Delayed Nyse Other stock markets 04:02:44 2023-11-30 pm EST			5-day change	1st Jan Change
102.48 ^USD	+1.33%		+0.79%	-7.63%

Nov. 30	Merck Says FDA Grants Priority Review to Application for Keytruda Plus Padcev for Urothelial Cancer Treatment	MT
Nov. 30	FDA Grants Priority Review to Merck's Application for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) for the First-Line Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer	CI

Latest news about Merck & Co., Inc.

Merck Says FDA Grants Priority Review to Application for Keytruda Plus Padcev for Urothelial Cancer Treatment	Nov. 30	MT
FDA Grants Priority Review to Merck's Application for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) for the First-Line Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer	Nov. 30	CI
Transcript : Merck & Co., Inc. Presents at The 6th Annual Evercore ISI HealthCONx Conference, Nov-30-2023 01:20 PM	Nov. 30	CI
Acclinate Collaborates with Merck to Increase Clinical Trial Diversity	Nov. 30	CI
Doubleverify Holdings Insider Sold Shares Worth $56,765,625, According to a Recent SEC Filing	Nov. 29	MT
Merck & Co., Inc. Announces Management Changes, Effective on December 4, 2023	Nov. 28	CI
Merck Raises Quarterly Dividend to $0.77 Per Share; Payable Jan. 8 to Shareholders of Record on Dec. 15	Nov. 28	MT
Merck Raises Quarterly Dividend 5.5% To 77 Cents	Nov. 28	DJ
Merck Declares Dividend for the First Quarter of 2024, Payable on January 8, 2024	Nov. 28	CI
Merck: promising results for pneumococcal vaccine	Nov. 28	CF
Merck Says Phase 3 Trial of Pneumococcal Disease Vaccine Candidate V116 Showed 'Strong Evidence' of Immunogenicity	Nov. 28	MT
Merck Announces Results from STRIDE-3, a Phase 3 Trial Evaluating V116	Nov. 28	CI
Hipgnosis Songs, founder Mercuriadis face legal claims	Nov. 23	RE
US Senate Health Committee Members Ask Johnson & Johnson, Merck, Bristol-Myers Squibb CEOs to Testify on Drug Pricing	Nov. 21	MT
Johnson & Johnson, Merck, Bristol Myers Squibb Invited to Testify to Senate Health Committee on Drug Prices	Nov. 21	MT

More news

Analyst Recommendations on Merck & Co., Inc.

Deutsche Bank Initiates Coverage on Merck & Company With Buy Rating, $115 Price Target	Nov. 09	MT
ANALYST RECOMMENDATIONS : Apple, ADP, Fortinet, General Motors, S&P...	Nov. 03
Morgan Stanley Adjusts Price Target on Merck & Company to $118 From $115, Maintains Equalweight Rating	Oct. 27	MT
BMO Capital Upgrades Merck & Company to Outperform From Market Perform, Raises Price Target to $132 From $113	Oct. 27	MT
ANALYST RECOMMENDATIONS : Amazon, Comcast, Intel, Merck, Roblox...	Oct. 27

More recommendations

Press releases Merck & Co., Inc.

FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) for the First-Line Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer	Nov. 30	BU
Merck's V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults, Demonstrated Superior Immunogenicity for 10 of 11 Unique Serotypes Compared to PCV20 in Adults 50 Years of Age and Older	Nov. 29	AQ
AWS and Accenture Help Merck Use Cloud Technology to Reduce Drug Discovery Time and Accelerate Clinical Trial Development	Nov. 29	BU
Merck Announces First-Quarter 2024 Dividend	Nov. 28	BU
Merck’s V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults, Demonstrated Superior Immunogenicity for 10 of 11 Unique Serotypes Compared to PCV20 in Adults 50 Years of Age and Older	Nov. 28	BU

More press releases

News in other languages on Merck & Co., Inc.

Merck : résultats prometteurs pour le vaccin pneumococcique	Nov. 28
MÄRKTE USA/Wall Street knapp im Minus - Fed-Protokoll kein Befreiungsschlag	Nov. 21
MÄRKTE USA/Wall Street mit leichten Abgaben - Fed-Protokoll im Blick	Nov. 21
MÄRKTE USA/Börsen mit leichten Abgaben - Fed-Protokoll im Blick	Nov. 21
MÄRKTE USA/Zurückhaltung vor Fed-Protokoll	Nov. 21

More news

Highs and lows

1 week

99.80

102.69

1 month

99.80

105.17

Current year

96.36

119.65

1 year

96.36

119.65

3 years

70.89

119.65

5 years

65.25

119.65

10 years

45.69

119.65

More quotes

Managers and Directors - Merck & Co., Inc.

Managers	Title	Age	Since
Robert Davis CEO	Chief Executive Officer	56	2014
Caroline Litchfield DFI	Director of Finance/CFO	54	1989
Dave Williams CTO	Chief Tech/Sci/R&D Officer	54	2020

Members of the board	Title	Age	Since
Tom Glocer BRD	Director/Board Member	63	2007
Pamela Craig BRD	Director/Board Member	65	2015
Inge Thulin BRD	Director/Board Member	69	2018

More insiders

ETFs positioned on Merck & Co., Inc.

Name	Weight	AuM	1st Jan change	Investor Rating
AGF U.S. MARKET NEUTRAL ANTI-BETA FUND - USD	14.34%	323 M€	-5.37%	-
FIRST TRUST NASDAQ PHARMACEUTICALS ETF - USD	7.37%	18 M€	-8.94%	-
INVESCO S&P 500 MOMENTUM ETF - USD	7.20%	212 M€	+8.58%

More ETFs positioned on Merck & Co., Inc.

Quotes

Date	Price	Change	Volume
23-11-30	102.48	+1.33%	29,299,666
23-11-29	101.13	+0.95%	10,286,779
23-11-28	100.18	-1.23%	8,738,483
23-11-27	101.43	-0.43%	7,356,536
23-11-24	101.87	+0.19%	3,167,952

Delayed Quote Nyse, November 30, 2023 at 04:02 pm EST

More quotes

Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (69.7%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.; - sale of vaccines (18%); - sale of animal health products (9.4%); - other (2.9%). Net sales are distributed geographically as follows: the United States (45.9%), Europe/Middle East/Africa (24.5%), China (8.8%), Japan (6.1%), Asia/Pacific (6.1%), Latin America (4.3%) and other (4.3%).

Sector

Pharmaceuticals

Calendar

2024-02-01 - Q4 2023 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Merck & Co., Inc.

Trading Rating :

Investor Rating :

ESG Refinitiv :

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

102.48USD

Average target price

123.61USD

Spread / Average Target

+20.62%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
MERCK & CO., INC.	-7.63%	256 B $
ELI LILLY AND COMPANY	+61.56%	532 B $
NOVO NORDISK A/S	+48.29%	452 B $
JOHNSON & JOHNSON	-12.45%	366 B $
ABBVIE INC.	-11.89%	245 B $
ROCHE HOLDING AG	-18.74%	217 B $
NOVARTIS AG	+1.83%	199 B $
ASTRAZENECA PLC	-9.73%	197 B $
PFIZER, INC.	-40.53%	170 B $
AMGEN INC.	+2.64%	143 B $

Other Pharmaceuticals

Sales 2023 *	59.92 B	Sales 2024 *	63.03 B	Capitalization	260 B
Net income 2023 *	630 M	Net income 2024 *	18.75 B	EV / Sales 2023 *	4,80x
Net Debt 2023 *	27.72 B	Net Debt 2024 *	15.62 B	EV / Sales 2024 *	4,37x
P/E ratio 2023 *	359x	P/E ratio 2024 *	13,5x	Employees	68,000
Yield 2023 *	2,88%	Yield 2024 *	3,16%	Free-Float	70.80%

Merck & Co., Inc. Stock price

Equities

MRK

US58933Y1055

Pharmaceuticals

Financials (USD)

Chart Merck & Co., Inc.

Latest news about Merck & Co., Inc.

Analyst Recommendations on Merck & Co., Inc.

Press releases Merck & Co., Inc.

News in other languages on Merck & Co., Inc.

Quotes and Performance

Highs and lows

Managers and Directors - Merck & Co., Inc.

ETFs positioned on Merck & Co., Inc.

Quotes

Company Profile

Income Statement Evolution

Ratings for Merck & Co., Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals

1 day	+1.33%
1 week	+0.79%
1 month	-0.21%
3 months	-5.96%
6 months	-7.18%
Current year	-7.63%